Clinical Trial Update: Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD [Phase 4]

View source ↗

Summary

Phase 4 trial comparing ranibizumab on an as-needed basis to aflibercept every two months for maintaining retinal thickness stability in neovascular age-related…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• Aflibercept (Aflibercept)
• Ranibizumab (ranibizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Neovascular Age-related Macular Degeneration | Phase 4 | Status: COMPLETED | Results posted: 2019-03-21